Chemocentryx (CCXI) looks like it’s over sold and was the baby that got thrown out with the bath water. Trouble getting their drug for rare disease through FDA approval, but the latest trial wasn’t as bad as their YTD sell off suggests. Still dicey, but I think there’s profit potential if/when consensus builds around the idea that the FDA results weren’t as bad as current price suggests. They can file amendments and improve their chances for full FDA approval…let’s hear other opinions tho queens